Oxidative Stress Markers Predict Treatment Outcomes in Patients with Generalized Anxiety Disorder Treated with Selective Serotonin Reuptake Inhibitors
Neuropsychobiology · 12.03.2025 · 84 (3) · 146-157
DOI: 10.1159/000544963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychobiology, online erschienen am 12.03.2025. Verfasst von Lijun Cui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Psychiatry, Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou, China. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Anxiety Disorders, Oxidative Stress, Sertraline. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Introduction
The etiology of generalized anxiety disorder (GAD) has not been fully understood, and oxidative stress may potentially contribute to its pathogenesis. However, there is no published evidence concerning the possible influence of oxidative stress on antidepressant treatment outcomes. This study investigated the ability of oxidative stress markers to predict treatment outcomes in GAD patients treated with selective serotonin reuptake inhibitors (SSRIs).
Methods
One hundred-one GAD patients and 100 healthy controls (HCs) were included in this study. The 101 GAD patients were selected for treatment with escitalopram (n = 52) or sertraline (n = 49) for 8 weeks. Hamilton Anxiety Rating Scale (HAM-A) assessments were conducted before and after treatment. The serum levels of eight oxidative stress makers, malondialdehyde (MDA), lipid hydroperoxides (LPO), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), cortisol, high-density lipoprotein (HDL), and nitric oxide (NO) were measured using enzyme-linked immunosorbent assays (ELISA) before and after SSRI treatment in GAD patients and at the time of HC enrollment.
Results
The serum levels of MDA, cortisol, and LPO were higher in GAD patients than in HCs (all p < 0.001), while SOD, GSH-Px, and CAT were lower than in HCs (all p < 0.001). The baseline MDA, LPO, NO, and cortisol levels were positively correlated with anxiety severity, while GSH-Px was negatively correlated. After 8 weeks of SSRI treatment, the GSH-Px levels increased, and MDA and LPO decreased (all p < 0.05). Alterations in MDA levels covaried with changes in anxiety measures (all p < 0.05). The ability of the receiver-operating characteristic (ROC) area of the baseline MDA levels to predict the SSRI endpoint treatment response was 0.804 (p < 0.05).
Conclusion
The pathogenesis of GAD might involve oxidative stress. Moreover, serum MDA levels might predict treatment response to SSRIs. However, more research is warranted to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Psychiatry, Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou, China.
- Laboratory of Translational Psychiatry, Hangzhou Seventh Municipal Hospital, Hangzhou, China.
- Department of Neurosis and Psychosomatic Diseases, Huzhou Third Municipal Hospital, Hangzhou Seventh Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou, China.
Zitieren
APA
Cui, L., Lu, J., Shen, Z., Zhu, J., Chen, H., Yang, S., Wang, S., & Shen, X. (2025). Oxidative Stress Markers Predict Treatment Outcomes in Patients with Generalized Anxiety Disorder Treated with Selective Serotonin Reuptake Inhibitors. Neuropsychobiology, 84(3), 146-157. https://doi.org/10.1159/000544963
Vancouver
Cui L, Lu J, Shen Z, Zhu J, Chen H, Yang S, et al. Oxidative Stress Markers Predict Treatment Outcomes in Patients with Generalized Anxiety Disorder Treated with Selective Serotonin Reuptake Inhibitors. Neuropsychobiology. 2025;84(3):146-157. doi:10.1159/000544963
BibTeX
@article{Cui2025,
author = {Cui, Lijun and Lu, Jingjing and Shen, Zhongxia and Zhu, Jielin and Chen, Huanxin and Yang, Shenliang and Wang, Shikai and Shen, Xinhua},
title = {Oxidative Stress Markers Predict Treatment Outcomes in Patients with Generalized Anxiety Disorder Treated with Selective Serotonin Reuptake Inhibitors},
journal = {Neuropsychobiology},
year = {2025},
volume = {84},
number = {3},
pages = {146--157},
doi = {10.1159/000544963}
}
EUVIMED